EUVIMEDEUVIMED entdecken
Open Access

Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost

Genghao Chen iD, Thao Nguyen iD, Lindsay G A McKay iD, Sravya Sowdamini Nakka, Pan Hu iD, Julia McBride iD, Anthony C Liang iD, Rachel Olson iD, James J Moon iD, Andrew D Luster iD, Anthony Griffiths, Stephen J Elledge iD

Science Advances · 21.11.2025 · 11 (47)

DOI: 10.1126/sciadv.adx0037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 21.11.2025. Verfasst von Genghao Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, COVID-19, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of SARS-CoV-2 variants has challenged the current spike protein–focused COVID-19 vaccine strategy due to neutralizing antibody escape and waning antibody-mediated immunity. In contrast, T cell–mediated immunity targeting conserved epitopes may offer broad and long-lasting protection. However, whether T cells alone can provide sufficient protection remains unclear. Here, we identified both Omicron BA.1–specific and ancestral (Wuhan)–conserved CD8 T cell epitopes in the SARS-CoV-2 spike protein and evaluated them as carrier-protein fusion vaccines in mouse models. Subcutaneous immunizations with two CD8 epitope peptides substantially lowered lung viral load and conferred protection against low-dose viral challenge, but not against high-dose challenge. Notably, intranasal boosting—with or without adjuvant—enhanced lung resident memory T cell responses and conferred potent, durable protection against high-dose infection. These findings emphasize the importance of mucosal vaccination to boost protective T cell immunity against SARS-CoV-2 and support the potential of T cell–based vaccines targeting conserved epitopes for broad immunity against SARS-CoV-2 and other respiratory viral threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesCOVID-19CD8-Positive T-LymphocytesEpitopes, T-LymphocyteEpitopes, B-LymphocyteAnimalsSpike Glycoprotein, CoronavirusMiceAdministration, IntranasalFemaleImmunization, SecondaryHumansMice, Inbred BALB CViral LoadAntibodies, Viral

Substanzen

COVID-19 VaccinesSpike Glycoprotein, CoronavirusEpitopes, T-Lymphocytespike protein, SARS-CoV-2Epitopes, B-LymphocyteAntibodies, Viral

Autor:innen und Institutionen

  • Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA 02129, USA.
  • National Emerging Infectious Diseases Laboratories (NEIDL) and Department of Virology, Immunology, and Microbiology, Boston University Medical School, Boston, MA 02118, USA.
  • Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.

ORCID-Profile: Genghao Chen, Thao Nguyen, Lindsay G A McKay, Pan Hu, Julia McBride, Anthony C Liang, Rachel Olson, James J Moon, Andrew D Luster, Stephen J Elledge

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
  • Massachusetts Consortium on Pathogen Readiness

Zitieren

APA

Chen, G., Nguyen, T., McKay, L. G. A., Nakka, S. S., Hu, P., McBride, J., Liang, A. C., Olson, R., Moon, J. J., Luster, A. D., Griffiths, A., & Elledge, S. J. (2025). Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost. Science Advances, 11(47). https://doi.org/10.1126/sciadv.adx0037

Vancouver

Chen G, Nguyen T, McKay LGA, Nakka SS, Hu P, McBride J, et al. Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost. Science Advances. 2025;11(47). doi:10.1126/sciadv.adx0037

BibTeX
@article{Chen2025,
  author = {Chen, Genghao and Nguyen, Thao and McKay, Lindsay G A and Nakka, Sravya Sowdamini and Hu, Pan and McBride, Julia and Liang, Anthony C and Olson, Rachel and Moon, James J and Luster, Andrew D and Griffiths, Anthony and Elledge, Stephen J},
  title = {Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {47},
  doi = {10.1126/sciadv.adx0037}
}
Kostenlos starten →